Idarucizumab since FDA approval: Use in the real-world.
Publication
, Journal Article
Ebinger, J; Granger, CB; Zhu, A; Chang, A; Henry, TD
Published in: Am Heart J
November 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
November 2017
Volume
193
Start / End Page
93 / 94
Location
United States
Related Subject Headings
- Venous Thrombosis
- United States
- Humans
- Drug Approval
- Cardiovascular System & Hematology
- Antibodies, Monoclonal, Humanized
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ebinger, J., Granger, C. B., Zhu, A., Chang, A., & Henry, T. D. (2017). Idarucizumab since FDA approval: Use in the real-world. Am Heart J, 193, 93–94. https://doi.org/10.1016/j.ahj.2017.08.007
Ebinger, Joseph, Christopher B. Granger, Alexander Zhu, Allison Chang, and Timothy D. Henry. “Idarucizumab since FDA approval: Use in the real-world.” Am Heart J 193 (November 2017): 93–94. https://doi.org/10.1016/j.ahj.2017.08.007.
Ebinger J, Granger CB, Zhu A, Chang A, Henry TD. Idarucizumab since FDA approval: Use in the real-world. Am Heart J. 2017 Nov;193:93–4.
Ebinger, Joseph, et al. “Idarucizumab since FDA approval: Use in the real-world.” Am Heart J, vol. 193, Nov. 2017, pp. 93–94. Pubmed, doi:10.1016/j.ahj.2017.08.007.
Ebinger J, Granger CB, Zhu A, Chang A, Henry TD. Idarucizumab since FDA approval: Use in the real-world. Am Heart J. 2017 Nov;193:93–94.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
November 2017
Volume
193
Start / End Page
93 / 94
Location
United States
Related Subject Headings
- Venous Thrombosis
- United States
- Humans
- Drug Approval
- Cardiovascular System & Hematology
- Antibodies, Monoclonal, Humanized
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology